[
  {
    "ts": null,
    "headline": "Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright",
    "summary": "Discover how Hims & Hers Health, Inc. is disrupting the obesity drug market amid regulatory changes. Learn what investors should know now. Click for more on HIMS.",
    "url": "https://finnhub.io/api/news?id=514a240f3b8c403dc1c37a5d965dad6517b50e88d5d1c94bbbdd159413993065",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760990823,
      "headline": "Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright",
      "id": 137171135,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1829882171/image_1829882171.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover how Hims & Hers Health, Inc. is disrupting the obesity drug market amid regulatory changes. Learn what investors should know now. Click for more on HIMS.",
      "url": "https://finnhub.io/api/news?id=514a240f3b8c403dc1c37a5d965dad6517b50e88d5d1c94bbbdd159413993065"
    }
  },
  {
    "ts": null,
    "headline": "RANI: Chugai Deal Announced",
    "summary": "By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT With investors perched on the edge of their seats for months, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) announces a deal including upfront milestones and partner-funded asset development. On October 18 th Rani and Chugai Pharmaceutical disclosed a collaboration and license agreement that includes a $10 million upfront",
    "url": "https://finnhub.io/api/news?id=e7bb4fa5366528cb12c0e5afd0ca6e855f944635018b2704491377c46f64004f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760972760,
      "headline": "RANI: Chugai Deal Announced",
      "id": 137174025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT With investors perched on the edge of their seats for months, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) announces a deal including upfront milestones and partner-funded asset development. On October 18 th Rani and Chugai Pharmaceutical disclosed a collaboration and license agreement that includes a $10 million upfront",
      "url": "https://finnhub.io/api/news?id=e7bb4fa5366528cb12c0e5afd0ca6e855f944635018b2704491377c46f64004f"
    }
  },
  {
    "ts": null,
    "headline": "Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai",
    "summary": "Rani Therapeutics secured a $1.085 billion collaboration with Chugai Pharmaceutical. Check out why I am initiating with a Buy rating on RANI stock.",
    "url": "https://finnhub.io/api/news?id=36347ac5912198470ef5396583d7edf28434e74c3f7179483889fa5c4a692083",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760970015,
      "headline": "Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai",
      "id": 137169339,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2233124313/image_2233124313.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Rani Therapeutics secured a $1.085 billion collaboration with Chugai Pharmaceutical. Check out why I am initiating with a Buy rating on RANI stock.",
      "url": "https://finnhub.io/api/news?id=36347ac5912198470ef5396583d7edf28434e74c3f7179483889fa5c4a692083"
    }
  },
  {
    "ts": null,
    "headline": "My Top 3 Pharma Stocks",
    "summary": "Discover the top 3 Big Pharma stocks beating forecasts and offering high dividends.",
    "url": "https://finnhub.io/api/news?id=16b7d42a7ab56fff4cf263eccf8bc6b046116accec4a8334c5f7f3ce0f4d8cee",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760960303,
      "headline": "My Top 3 Pharma Stocks",
      "id": 137168226,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1039670620/image_1039670620.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover the top 3 Big Pharma stocks beating forecasts and offering high dividends.",
      "url": "https://finnhub.io/api/news?id=16b7d42a7ab56fff4cf263eccf8bc6b046116accec4a8334c5f7f3ce0f4d8cee"
    }
  },
  {
    "ts": null,
    "headline": "ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer",
    "summary": "These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.",
    "url": "https://finnhub.io/api/news?id=c37a61be624b1a13a5fb515b6b8eab015e04a8fb8b7020ebd95a877ece503b86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760958154,
      "headline": "ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer",
      "id": 137174026,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These Phase III results could enhance Verzenio’s uptake alongside ET in the adjuvant breast cancer setting, if approved.",
      "url": "https://finnhub.io/api/news?id=c37a61be624b1a13a5fb515b6b8eab015e04a8fb8b7020ebd95a877ece503b86"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: Healthcare Sector Dashboard For October",
    "summary": "Healthcare providers and pharmaceuticals/biotechnology subsectors are undervalued versus 11-year averages, with pharma/biotech also showing strong quality metrics. Read the full analysis.",
    "url": "https://finnhub.io/api/news?id=7e5e4d81e7f7bbf4ace2094dc8b479304205e7043756c5390b7cef95e12da826",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760955567,
      "headline": "IXJ: Healthcare Sector Dashboard For October",
      "id": 137167977,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1409850701/image_1409850701.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Healthcare providers and pharmaceuticals/biotechnology subsectors are undervalued versus 11-year averages, with pharma/biotech also showing strong quality metrics. Read the full analysis.",
      "url": "https://finnhub.io/api/news?id=7e5e4d81e7f7bbf4ace2094dc8b479304205e7043756c5390b7cef95e12da826"
    }
  },
  {
    "ts": null,
    "headline": "These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond",
    "summary": "These companies are jockeying for position in a potential $150 billion market opportunity.",
    "url": "https://finnhub.io/api/news?id=03552d894fb9af38868f1a57faf53a50facb7bd5e32e28a05eb593fe0b9140a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760948400,
      "headline": "These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond",
      "id": 137174027,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These companies are jockeying for position in a potential $150 billion market opportunity.",
      "url": "https://finnhub.io/api/news?id=03552d894fb9af38868f1a57faf53a50facb7bd5e32e28a05eb593fe0b9140a9"
    }
  }
]